Today’s antihyperglycemic drugs target a variety of pathological mechanisms implicated in T2DM, ranging from insulin secretion (e.g., SUs), peripheral glucose uptake (e.g., biguanides) and glucose reabsorption (e.g., SGLT2 inhibitors) (Chaudhury et al., 2017). Here, SLC5A2 is linked to type 2 diabetes mellitus.